Home » Newsletters » BioWorld Science

BioWorld Science

June 17, 2008

View Archived Issues

Lilly and TransPharma enter licensing agreement for ViaDerm-hPTH for osteoporosis

Vical receives funding from AnGes for phase III trial of Allovectin-7

Invitrogen acquires Applied Biosystems from Applera

Z-360 safe when combined with gemcitabine in pancreatic cancer patients

Phase I studies characterize MK-0646 in solid tumor patients

Novel compounds for inflammatory disorders claimed in recent patents

Nastech changes name to MDRNA

Dimethyl fumarate shows dual neuroprotective and antiinflammatory effects in multiple sclerosis

Pfizer patents novel sulopenem prodrugs

Novel antidiabetic agents disclosed in recent patent literature

Positive clinical results from studies on JAK2 inhibitor INCB-018424 reported

Victory Pharma's MGX-006 enters first of two clinical studies for pivotal development program

Pfizer completes acquisition of Encysive Pharmaceuticals

The FDA approves Lilly's Cymbalta for fibromyalgia

Transdel and Cato collaborate on phase III Ketotrandel program

Positive phase II results reported for once-daily Arikace in cystic fibrosis

Preclinical profile of novel antidiabetic compound P-1736-05 reported

Lipoxen receives grant from IAVI to research improved HIV vaccine delivery using ImuXen

DSM and Crucell achieve new record in production of IgG antibodies using PER.C6

Opko Health acquires exclusive worldwide rights to Redox's Doxovir for viral conjunctivitis

LLS and Aegera to initiate phase I/II trial of targeted blood cancer therapy AEG-35156

GSK and Mpex enter alliance to develop EPI drug candidates for bacterial infections

Enrollment completed for phase II clinical trial of TRO-19622 in diabetic neuropathy

Acadia's ACP-104 for schizophrenia does not meet endpoints in phase IIb trial

NanoViricides HivCide-I improves survival time in animal HIV study

Allergan receives FDA approval for Trivaris for ophthalmic indications

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...